These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17073675)

  • 1. Multiple sclerosis therapy monitoring based on gene expression.
    Goertsches R; Serrano-Fernández P; Möller S; Koczan D; Zettl UK
    Curr Pharm Des; 2006; 12(29):3761-79. PubMed ID: 17073675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis.
    Malhotra S; Río J; Urcelay E; Nurtdinov R; Bustamante MF; Fernández O; Oliver B; Zettl U; Brassat D; Killestein J; Lechner-Scott J; Drulovic J; Chan A; Martinelli-Boneschi F; García-Merino A; Montalban X; Comabella M
    Brain; 2015 Mar; 138(Pt 3):644-52. PubMed ID: 25586466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MS therapy research applying genome-wide RNA profiling of peripheral blood.
    Goertsches R; Zettl UK
    Int MS J; 2007 Sep; 14(3):98-107. PubMed ID: 18028834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy monitoring in patients with multiple sclerosis based on transcriptomic analysis].
    Zettl UK; Goertsches RH
    Fortschr Neurol Psychiatr; 2009 Aug; 77 Suppl 1():S64-8. PubMed ID: 19685398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy.
    Singh MK; Scott TF; LaFramboise WA; Hu FZ; Post JC; Ehrlich GD
    J Neurol Sci; 2007 Jul; 258(1-2):52-9. PubMed ID: 17467740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is it time to consider rationalizing IFN-beta treatment in individuals with multiple sclerosis?
    Giovannoni G
    J Neurol Neurosurg Psychiatry; 2004 Sep; 75(9):1234. PubMed ID: 15314107
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs.
    Tsareva E; Kulakova O; Boyko A; Favorova O
    Pharmacogenet Genomics; 2016 Mar; 26(3):103-15. PubMed ID: 26678572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β.
    De Felice B; Mondola P; Sasso A; Orefice G; Bresciamorra V; Vacca G; Biffali E; Borra M; Pannone R
    BMC Med Genomics; 2014 May; 7():26. PubMed ID: 24885345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for interferon response in MS: are we there yet?
    Rudick RA; Ransohoff RM
    Neurology; 2008 Mar; 70(13 Pt 2):1069-70. PubMed ID: 18362268
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
    Mahurkar S; Suppiah V; O'Doherty C
    Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
    Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR
    Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Genetic Markers for Personalized Therapy of Polygenic Diseases: Pharmacogenetics of Multiple Sclerosis].
    Tsareva EY; Favorova OO; Boyko AN; Kulakova OG
    Mol Biol (Mosk); 2019; 53(4):574-599. PubMed ID: 31397433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elastic net-based prediction of IFN-β treatment response of patients with multiple sclerosis using time series microarray gene expression profiles.
    Fukushima A; Sugimoto M; Hiwa S; Hiroyasu T
    Sci Rep; 2019 Feb; 9(1):1822. PubMed ID: 30755676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interferon -beta therapy in multiple sclerosis].
    Satoh J
    Nihon Rinsho; 2006 Jul; 64(7):1297-309. PubMed ID: 16838648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomics and proteomics: role in the management of multiple sclerosis.
    Kappos L; Achtnichts L; Dahlke F; Kuhle J; Naegelin Y; Sandbrink R; Lindberg RL
    J Neurol; 2005 Sep; 252 Suppl 3():iii21-iii27. PubMed ID: 16170496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment.
    Alvarez-Lafuente R; Blanco-Kelly F; Garcia-Montojo M; Martínez A; De Las Heras V; Dominguez-Mozo MI; Bartolome M; Garcia-Martinez A; De la Concha EG; Urcelay E; Arroyo R
    Mult Scler; 2011 May; 17(5):513-20. PubMed ID: 21177319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An inventory of short term and long term changes in gene expression under interferon β treatment of relapsing remitting MS patients.
    Paap BK; Hundeshagen A; Hecker M; Zettl UK
    Curr Pharm Des; 2012; 18(29):4475-84. PubMed ID: 22612748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-beta: mechanism of action and dosing issues.
    Markowitz CE
    Neurology; 2007 Jun; 68(24 Suppl 4):S8-11. PubMed ID: 17562848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis.
    Byskosh PV; Reder AT
    Mult Scler; 1996 Apr; 1(5):262-9. PubMed ID: 9345428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.
    Sellebjerg F; Krakauer M; Hesse D; Ryder LP; Alsing I; Jensen PE; Koch-Henriksen N; Svejgaard A; Soelberg Sørensen P
    Eur J Neurol; 2009 Dec; 16(12):1291-8. PubMed ID: 19558503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.